Send mail to Author

Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors (Article)

Please indicate your contact information and select, which author you want to contact.



 
  _____    __   __             _    _      _____    ______  
 / ____||  \ \\/ //     ___   | || | ||   / ___//  /_   _// 
/ //---`'   \ ` //     /   || | || | ||   \___ \\   -| ||-  
\ \\___      | ||     | [] || | \\_/ ||   /    //   _| ||_  
 \_____||    |_||      \__ ||  \____//   /____//   /_____// 
  `----`     `-`'       -|_||   `---`   `-----`    `-----`  
                         `-`
 


Back to frontdoor view

OPUS4 Logo